Skip to main content
SpringerLink
Log in

Management of Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  • Chapter
  • First Online:
Blistering Diseases

Abstract

Erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immune-mediated disorders with distinct pathogenesis, clinical manifestations and prognosis. The management of these conditions is controversial due to a lack of well-designed randomised controlled trials. Removal of the offending agent, in-hospital management and regular surveillance for superimposed infection are basic requirements in the management of EM, SJS and TEN. The evidence supporting corticosteroids, immunosuppressants, antibiotics and biologic agents is lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wei CY, et al. A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet. 2012;27(1):132–41.

    Article  CAS  PubMed  Google Scholar 

  2. Revuz J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–5.

    Article  CAS  PubMed  Google Scholar 

  3. Lebargy F, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23(12):1237–44.

    Article  CAS  PubMed  Google Scholar 

  4. Bastuji-Garin S, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.

    Article  CAS  PubMed  Google Scholar 

  5. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181–200.

    Article  PubMed  Google Scholar 

  6. Guegan S, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126(2):272–6.

    Article  CAS  PubMed  Google Scholar 

  7. Paquet P, Pierard GE. Intense pulsed light treatment of persistent facial hypermelanosis following drug-induced toxic epidermal necrolysis. Dermatol Surg. 2004;30(12 Pt 2):1522–5.

    PubMed  Google Scholar 

  8. Haber J, et al. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26(1):33–41.

    Article  PubMed  Google Scholar 

  9. Garcia-Doval I, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.

    Article  CAS  PubMed  Google Scholar 

  10. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg. 1998;102(4):1018–22.

    Article  CAS  PubMed  Google Scholar 

  11. Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100–4.

    Article  PubMed  Google Scholar 

  12. Majumdar S, et al. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev. 2002;(4):CD001435.

    Google Scholar 

  13. Wolkenstein P, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352(9140):1586–9.

    Article  CAS  PubMed  Google Scholar 

  14. Schulz JT, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21(3):199–204.

    Article  CAS  PubMed  Google Scholar 

  15. Downey A, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995–1003.

    Article  CAS  PubMed  Google Scholar 

  16. Daniel BS, et al. Concurrent management of toxic epidermal necrolysis with thermal water spray and non-stick dressings. Acta Dermatovenerol Croat. 2012;20(3):210–2.

    PubMed  Google Scholar 

  17. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil. 1997;18(6):520–4.

    Article  CAS  PubMed  Google Scholar 

  18. Halebian PH, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204(5):503–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. van der Meer JB, et al. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol. 2001;26(8):654–6.

    Article  PubMed  Google Scholar 

  20. Araki Y, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147(6):1004–11. 1011 e1.

    Article  CAS  PubMed  Google Scholar 

  21. Viard I, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–3.

    Article  CAS  PubMed  Google Scholar 

  22. Fernando SL. The management of toxic epidermal necrolysis. Australas J Dermatol. 2012;53(3):165–71.

    Article  PubMed  Google Scholar 

  23. Schneck J, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33–40.

    Article  PubMed  Google Scholar 

  24. Walsh S, Creamer D. IVIg in TEN: time to re-evaluate the efficacy of intravenous immunoglobulin in the management of toxic epidermal necrolysis. Br J Dermatol. 2012;167(2):230–1.

    Article  CAS  PubMed  Google Scholar 

  25. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167(2):424–32.

    Article  CAS  PubMed  Google Scholar 

  26. Jarrett P, et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol. 1997;22(3):146–7.

    Article  CAS  PubMed  Google Scholar 

  27. Renfro L, Grant-Kels JM, Daman LA. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol. 1989;28(7):441–4.

    Article  CAS  PubMed  Google Scholar 

  28. Valeyrie-Allanore L, et al. Open trial of cyclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53.

    Article  CAS  PubMed  Google Scholar 

  29. Reese D, et al. Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis. 2011;87(1):24–9.

    PubMed  Google Scholar 

  30. Szczeklik W, et al. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis. Ther Apher Dial. 2010;14(3):354–7.

    Article  CAS  PubMed  Google Scholar 

  31. Bamichas G, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6(3):225–8.

    Article  PubMed  Google Scholar 

  32. Chaidemenos GC, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36(3):218–21.

    Article  CAS  PubMed  Google Scholar 

  33. Yamada H, et al. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher. 1998;2(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  34. Furubacke A, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med. 1999;25(11):1307–10.

    Article  CAS  PubMed  Google Scholar 

  35. Frangogiannis NG, et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J. 1996;89(10):1001–3.

    Article  CAS  PubMed  Google Scholar 

  36. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol. 1991;25(5 Pt 1):778–86.

    Article  CAS  PubMed  Google Scholar 

  37. Arevalo JM, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48(3):473–8.

    Article  CAS  PubMed  Google Scholar 

  38. Yung-Yi Lee, et al. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatologica Sinica. 2013:31(2):78–81.

    Google Scholar 

  39. Rzany B, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769–73.

    Article  CAS  PubMed  Google Scholar 

  40. Assier H, et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539–43.

    Article  CAS  PubMed  Google Scholar 

  41. Roujeau JC. Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol. 1993;11(4):493–500.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, St. George Hospital, Sydney, NSW, Australia

    Benjamin S. Daniel BA, BCom, MBBS, M Med (Clin Epi) (Hons)

  2. Department of Dermatology, CHU Charles Nicolle, Rouen, France

    Pascal Joly MD, PhD

  3. Department of Dermatology, St. George Hospital, University of NSW Medical School, Sydney, NSW, Australia

    Dédée F. Murrell MA(Camb), BMBCh(Oxf), FAAD, MD, FACD, FRCP

Authors
  1. Benjamin S. Daniel BA, BCom, MBBS, M Med (Clin Epi) (Hons)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Joly MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dédée F. Murrell MA(Camb), BMBCh(Oxf), FAAD, MD, FACD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dédée F. Murrell MA(Camb), BMBCh(Oxf), FAAD, MD, FACD, FRCP .

Editor information

Editors and Affiliations

  1. Department of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia

    Dédée F. Murrell

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Daniel, B.S., Joly, P., Murrell, D.F. (2015). Management of Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Murrell, D. (eds) Blistering Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45698-9_66

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45698-9_66

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45697-2

  • Online ISBN: 978-3-662-45698-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation